161 related articles for article (PubMed ID: 28620989)
1. Recurrent angular cheilitis after secukinumab injections.
Hitaka T; Sawada Y; Okada E; Nakamura M
Australas J Dermatol; 2018 Feb; 59(1):e79-e80. PubMed ID: 28620989
[No Abstract] [Full Text] [Related]
2. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
[No Abstract] [Full Text] [Related]
3. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
de Groot M; de Rie MA; Bos JD
Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
[No Abstract] [Full Text] [Related]
4. Eczematous eruption in patients with psoriasis during risankizumab treatment.
Kromer C; Schön MP; Mössner R
Eur J Dermatol; 2020 Oct; 30(5):599-601. PubMed ID: 33185530
[No Abstract] [Full Text] [Related]
5. Urticarial vasculitis due do infliximab.
Goulão J; Cunha H; Anes I; Bártolo E; Furtado C; Serrano P; Brandão FM
J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):882-3. PubMed ID: 18462298
[No Abstract] [Full Text] [Related]
6. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
Teraki Y; Takahashi A; Inoue Y; Takamura S
Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
[No Abstract] [Full Text] [Related]
7. Atopic-like dermatitis after secukinumab injection: A case report.
Burlando M; Cozzani E; Russo R; Parodi A
Dermatol Ther; 2019 Jan; 32(1):e12751. PubMed ID: 30238583
[No Abstract] [Full Text] [Related]
8. Anti IL-17 flared psoriasis in a patient on secukinumab.
Noell C; McQuade B; Gottlieb A; Rosmarin D
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
[No Abstract] [Full Text] [Related]
9. Secukinumab for psoriasis in a patient with hepatitis B.
Feaster B; Cline A; Feldman SR
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
[TBL] [Abstract][Full Text] [Related]
10. Recurrent allergic contact dermatitis and cheilitis due to castor oil.
le Coz CJ; Ball C
Contact Dermatitis; 2000 Feb; 42(2):114-5. PubMed ID: 10703646
[No Abstract] [Full Text] [Related]
11. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab-Induced Psoriasiform Eruption.
Sladden MJ; Sladden CS; Gulliver WPF
JAMA Dermatol; 2017 Nov; 153(11):1194-1195. PubMed ID: 28768308
[No Abstract] [Full Text] [Related]
13. Does adalimumab cause bullous pemphigoid?
Toosi S; Bystryn JC
Clin Exp Dermatol; 2010 Oct; 35(7):795. PubMed ID: 20831605
[No Abstract] [Full Text] [Related]
14. Adverse skin reaction to Secukinumab.
Peigottu MF; Montesu MA
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e432-e433. PubMed ID: 28370441
[No Abstract] [Full Text] [Related]
15. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
16. Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect?
Loi C; Patrizi A; Sechi A; Tartari F; Magnano M; Bardazzi F
G Ital Dermatol Venereol; 2018 Aug; 153(4):590-591. PubMed ID: 29767491
[No Abstract] [Full Text] [Related]
17. Rebound pustular psoriasis after brodalumab discontinuation.
Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
[No Abstract] [Full Text] [Related]
18. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.
Quach OL; Hsu S
JAMA Dermatol; 2016 Apr; 152(4):486-7. PubMed ID: 26720159
[No Abstract] [Full Text] [Related]
19. Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis.
Wang LC; Medenica MM; Shea CR; Busbey S
J Am Acad Dermatol; 2003 Jul; 49(1):157-8. PubMed ID: 12833033
[No Abstract] [Full Text] [Related]
20. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
